11 research outputs found
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
Characterization of haematological parameters with bortezomib--melphalan--prednisone versus melphalan--prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial
P>Although haematological toxicities, such as anaemia, are common in
multiple myeloma (MM), no clear consensus exists on the use and impact
of erythropoiesis-stimulating agents (ESA) on outcomes in MM. This
analysis characterizes haematological toxicities and associated
interventions in the phase III VISTA (Velcade (R) as Initial Standard
Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone)
study of bortezomib plus melphalan/prednisone (VMP, n = 344) versus MP
(n = 338) in previously untreated MM patients ineligible for high-dose
therapy, and evaluates the impact of ESA use or red-blood-cell (RBC)
transfusions on outcomes and thromboembolic risk. Incidence of
haematological toxicities was similar with VMP and MP; similar rates of
interventions and associated complications (e.g. bleeding, febrile
neutropenia) were observed. Two hundred thirty three patients received
ESA; 204 had RBC transfusions. Frequency of thromboembolic events was
low and not affected by ESA use. Median time-to progression (TTP) was
similar between ESA/non-ESA [hazard ratio: 1 center dot 03 (95%
confidence interval 0 center dot 76-1 center dot 39); P = 0 center dot
8478] in both arms (VMP: 19 center dot 9/not reached; MP: 15 center dot
0/17 center dot 5 months). Three-year overall survival (OS) rates were
similar between ESA/non-ESA in each arm. Patients receiving RBC
transfusions had significantly shorter OS (P < 0 center dot 0001) versus
non-RBC-transfusion patients. In conclusion, bortezomib did not add to
melphalan haematological toxicity. Concomitant ESA use with VMP/MP in
previously untreated MM patients did not adversely affect TTP or OS, or
increase thromboembolic risk. However, RBC transfusion was associated
with significantly shorter survival
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial
Although haematological toxicities, such as anaemia, are common in multiple myeloma (MM), no clear consensus exists on the use and impact of erythropoiesis-stimulating agents (ESA) on outcomes in MM. This analysis characterizes haematological toxicities and associated interventions in the phase III VISTA (Velcade ® as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone) study of bortezomib plus melphalan/prednisone (VMP, n=344) versus MP (n=338) in previously untreated MM patients ineligible for high-dose therapy, and evaluates the impact of ESA use or red-blood-cell (RBC) transfusions on outcomes and thromboembolic risk. Incidence of haematological toxicities was similar with VMP and MP; similar rates of interventions and associated complications (e.g. bleeding, febrile neutropenia) were observed. Two hundred thirty three patients received ESA; 204 had RBC transfusions. Frequency of thromboembolic events was low and not affected by ESA use. Median time-to progression (TTP) was similar between ESA/non-ESA [hazard ratio: 1·03 (95% confidence interval 0·76-1·39); P=0·8478] in both arms (VMP: 19·9/not reached; MP: 15·0/17·5months). Three-year overall survival (OS) rates were similar between ESA/non-ESA in each arm. Patients receiving RBC transfusions had significantly shorter OS (P<0·0001) versus non-RBC-transfusion patients. In conclusion, bortezomib did not add to melphalan haematological toxicity. Concomitant ESA use with VMP/MP in previously untreated MM patients did not adversely affect TTP or OS, or increase thromboembolic risk. However, RBC transfusion was associated with significantly shorter survival. © 2011 Blackwell Publishing Ltd
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia
Addition of rituximab (R) to fludarabine and cyclophosphamide (FC) has significantly improved patient outcomes in chronic lymphocytic leukemia (CLL). Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined. We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH, a study of FC or R-FC in relapsed CLL. An independent test set was derived from 282 pretreatment specimens from CLL8, a study of FC or R-FC in treatment-naive patients. Genes specific for benefit from R-FC were determinedby assessing treatment-gene interactions in Cox proportional hazards models. REACH patients with higher pretreatment protein tyrosine kinase 2 (PTK2) messenger RNA levels derived greater benefit from R-FC, with significant improvements in progression-free survival, independent of known prognostic factors in a multivariate model. Examination of PTK2 gene expression in CLL8 patients yielded similar results. Furthermore, PTK2 inhibition blunted R-dependent cell death in vitro. This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC. PTK2 expression may be a useful biomarker for patient selection in future trials. These trials were registered at www.clinicaltrials.gov as #NCT00090051 (REACH) and #NCT00281918 (CLL8)